Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1-Reference-Cited by-同舟云学术

Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1

Published:2019-09 Issue: Volume:192 Page:105115
ISSN:0960-0760
Container-title:The Journal of Steroid Biochemistry and Molecular Biology
language:en
Short-container-title:The Journal of Steroid Biochemistry and Molecular Biology

Author:

Oksala Riikka,Moilanen Anu,Riikonen Reetta,Rummakko Petteri,Karjalainen Arja,Passiniemi Mikko,Wohlfahrt Gerd,Taavitsainen Päivi,Malmström Chira,Ramela Meri,Metsänkylä Hanna-Maija,Huhtaniemi Riikka,Kallio Pekka J.,Mustonen Mika VJ.

Funder

Orion Corporation, Orion Pharma, Finland

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference42 articles.

1. Cancer statistics;Siegel;CA Cancer J. Clin.,2015

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur. J. Cancer,2013

3. Characterising the castration-resistant prostate cancer population: a systematic review;Kirby;Int. J. Clin. Pract.,2011

4. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer;Linja;Cancer Res.,2001

5. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis;Scher;J. Clin. Oncol.,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PC Kz is the novel human prostate cancer model in vitro and in vivo;Russian Journal of Oncology;2023-12-20

2. Antiproliferative activity of the novel CYP17A1 inhibitor alsevirone;Russian Journal of Oncology;2023-12-20

3. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications;European Journal of Medicinal Chemistry;2023-09

4. Targeting androgen receptor degradation with PROTACs from bench to bedside;Biomedicine & Pharmacotherapy;2023-02

5. Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs;Bioorganic Chemistry;2022-11